MediPharm Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

MediPharm Labs şirketinin toplam hissedar öz sermayesi CA$47.6M ve toplam borcu CA$2.7M olup, bu da borç-öz sermaye oranını 5.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$59.8M ve CA$12.2M dir.

Anahtar bilgiler

5.7%

Borç/özkaynak oranı

CA$2.71m

Borç

Faiz karşılama oranı	n/a
Nakit	CA$16.47m
Eşitlik	CA$47.61m
Toplam yükümlülükler	CA$12.23m
Toplam varlıklar	CA$59.84m

Son finansal sağlık güncellemeleri

Recent updates

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

Oct 11

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

May 21

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Apr 06

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Mar 07

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Aug 18

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: LABS 'nin kısa vadeli varlıkları ( CA$37.9M ) kısa vadeli yükümlülüklerini ( CA$12.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: LABS şirketinin kısa vadeli varlıkları ( CA$37.9M ) uzun vadeli yükümlülüklerini ( CA$47.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: LABS şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: LABS şirketinin borç/öz sermaye oranı son 5 yılda 5% seviyesinden 5.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: LABS şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: LABS serbest nakit akışı her yıl % { 19 1.9 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

MediPharm Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

MediPharm Labs (TSE:LABS) Is Using Debt Safely

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Recent updates

MediPharm Labs Corp. Announces Executive Changes

MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations

MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

MediPharm Labs (TSE:LABS) Is Using Debt Safely

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

Consensus estimates of losses per share improve by 25%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

New minor risk - Share price stability

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 11%

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

CEO & Director exercised options to buy CA$130k worth of stock.

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

Consensus EPS estimates upgraded to CA$0.045 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Consensus revenue estimates increase by 47%, EPS downgraded

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Consensus revenue estimates fall by 20%

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to CA$0.25

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Consensus revenue estimates fall by 13%

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold CA$87k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?